Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
Alcon stock presents a clear valuation split right now. The intrinsic value estimate from a Discounted Cash Flow (DCF) approach points to a large upside gap, while earnings-based market multiples lean expensive and the share price has still delivered a 16.5% decline over the past 5 years.
Over the past 5 years, Alcon has delivered a 16.5% decline, which raises the bar for any valuation case that argues the stock is now attractively priced.
Recent news around Alcon’s partnership with RxSight and its push to expand training for premium cataract surgery can support expectations for future cash flows, but decisions to discontinue certain intraocular lens programs highlight execution and product outcome risks that can weigh on valuation.
Alcon scores 3 out of 6 on a broad set of valuation checks, which is a mixed picture rather than a clear bargain or clear overvaluation.
The issue now is whether the 42.5% discount implied by the Discounted Cash Flow (DCF) intrinsic value estimate is enough to outweigh the weaker long term share return record and the richer read from earnings multiples.
Find out why Alcon’s -13.6% return over the last year is lagging behind its peers.
Is Alcon Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) model values Alcon based on the cash the business is expected to generate for shareholders. On this view, the latest twelve-month free cash flow is about US$1.54b, with the model assuming that cash flows continue to grow rather than contract. That stream of cash is projected forward in two stages and discounted back to today.
This approach produces an estimated intrinsic value of around CHF105.44 per share. Compared with the current market price, that implies the stock screens about 42.5% undervalued. The decision to discontinue certain intraocular lens programs, as reported in 2024, helps explain why the price may still sit below this cash flow based estimate despite Alcon also highlighting higher 2026 earnings guidance.
On the DCF numbers alone, Alcon stock appears undervalued relative to the cash flows implied by the current share price.
Our Discounted Cash Flow (DCF) analysis suggests Alcon is undervalued by 42.5%. Track this in your watchlist or portfolio, or discover 257 more high quality undervalued stocks.
ALC Discounted Cash Flow as at Aug 2026
Does Alcon Look Pricey on Earnings?
Story Continues
For a profitable business like Alcon, the P/E ratio is a straightforward way to see what investors are paying for each unit of current earnings. Alcon trades at about 56.1x earnings, which is more than double the Medical Equipment industry average of roughly 24.7x and also well above the peer group average of about 28.6x.
The fair P/E for Alcon, based on factors such as its sector, profitability profile, size and risk, is estimated at around 40.5x. That is still a rich multiple, yet it sits well below where the stock currently trades. This points to a significant premium even after accounting for these company specific features.
On this P/E yardstick, Alcon stock appears clearly overvalued relative to both its sector and the modelled fair multiple.
SWX:ALC P/E Ratio as at Aug 2026
See what the numbers say about this price — find out in our valuation breakdown.
The Alcon Narrative: What Would Justify Today’s Price?
Simply Wall St Narratives pick up where the Alcon valuation split leaves off by spelling out the specific growth, margin and earnings paths that would need to hold for the stock to be worth materially more or less than today’s price on the Community page. Each narrative ties a fair value estimate to a clear story about Alcon’s potential catalysts and risks so you can track over time which version of events is actually unfolding.
The community is split on Alcon, with one camp focused on product expansion and capital returns while the other worries about pricing pressure and competition.
Bull case: 21% undervalued
“Accelerated new product launches including Unity VCS, PanOptix Pro, Tryptyr, Precision7, and recent pipeline accretive M&A provide significant near and medium term opportunities for share gain, mix improvement, and new market entry…”
Read the full Bull Case to see why Alcon could be undervalued
Bear case: 10% overvalued
“Escalating global healthcare cost containment measures and intensifying governmental price controls are likely to compress Alcon’s net margins over time, particularly as payers continue to reduce reimbursement rates for ophthalmic procedures and pharmaceuticals in both developed and emerging markets…”
Read the full Bear Case to see why Alcon could be overvalued
Do you think there’s more to the story for Alcon? Head over to our Community to see what others are saying!
The Bottom Line
Alcon sits between two conflicting valuation signals. The Discounted Cash Flow (DCF) intrinsic value estimate points to a meaningful discount to the current share price, while the elevated P/E multiple suggests the stock is overvalued relative to peers and a tailored fair ratio. That gap mainly reflects different views on future cash generation versus what the market is already paying for growth and execution. The key question from here is whether Alcon can deliver the cash flows and profitability that would justify both the current multiple and a potential closing of the DCF discount, or whether the valuation gap will ultimately prove to be a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ALC.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com